Recent IMRX News
- Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy • GlobeNewswire Inc. • 05/21/2026 09:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 11:52:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 11:43:39 AM
- Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 05/15/2026 11:35:00 AM
- Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting • GlobeNewswire Inc. • 04/21/2026 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/20/2026 08:16:11 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/20/2026 08:10:12 PM
- Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond • GlobeNewswire Inc. • 04/20/2026 01:00:00 PM
- Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/06/2026 08:05:00 PM
- Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival • GlobeNewswire Inc. • 03/17/2026 08:35:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2026 01:29:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 01:09:20 PM
- Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 03/06/2026 12:45:00 PM
- Immuneering to Present at the Leerink Global Healthcare Conference • GlobeNewswire Inc. • 03/02/2026 09:05:00 PM
- Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/18/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:44:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:37:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:32:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:22:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:14:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:10:18 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 01/22/2026 02:03:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/21/2026 02:09:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2026 09:07:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/15/2026 01:06:11 PM
